The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Is high-risk smoldering myeloma a misnomer – do these patients already have myeloma?
Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses whether high-risk smoldering multiple myeloma (SMM) is a biological misnomer and whether, based on genomic data, these individuals already have active myeloma. Dr Maura highlights that 10% of SMM cases show no evidence of malignant transformation and are termed genomic monoclonal gammopathy of undetermined significance (MGUS). While the remaining patients have evidence of neoplastic transformation, Dr Maura notes that this does not necessarily mean they will develop organ damage. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
